Description
UNLOXCYT (cosibelimab) is a monoclonal antibody that blocks PD-L1 to help the immune system fight cancer cells. It's given as an intravenous injection, with each vial containing 300 mg in 5 mL. Manufactured by Checkpoint Therapeutics, Inc., it's approved for prescription use. This information was generated using AI and is provided for informational and research purposes only.
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Cosibelimab | HTML | Access the FDA dataset for Cosibelimab — ANDA 761297 submitted by Mylan Institutional LLC | Open resource |